S&P 500

7,376.86

+23.13

+0.31%

Dow 30

51,285.73

-237.33

-0.46%

Nasdaq

24,579.42

+264.43

+1.09%

Russell 2000

2,754.11

+24.22

+0.89%

10-Yr Bond

4.8590

+0.0220

+0.45%

VIX

25.64

-2.54

-9.01%

Gold

4,074.90

-38.60

-0.94%

Bitcoin USD

75,877.56

+78.92

+0.10%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

Swiss - Delayed Quote CHF

Cosmo N.V. (CMHC.SW)

56.80 -1.30 (-2.24%)

At close: November 6 at 5:30:15 PM GMT+1

Loading Chart for CMHC.SW

Chart Range Bar

Interval:

In partnership with ChartIQ

Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis

Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice

Mobilize your Website

View Site in Mobile | Classic

Share by:

U.S. markets closed

Cosmo N.V. (CMHC.SW)

Recent News

Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis

Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice

Related Tickers